Our Publications

The following peer-reviewed publications are related to the development of the Teoreler PBPK modelling platform. Our models and simulations have been validated against observed data in these studies.

  1. Saeheng T, Karbwang J, Rajoli RKR, Siccardi M, Owen A, Na-Bangchang K. Physiologically-based Pharmacokinetic Modelling for Optimising Photoactivated Curcumin Dosing in Antimicrobial-Resistant Infections. Pharmaceutical Science: New Insights and Developments Vol. 6 2025; pp. 146-160. https://doi.org/10.9734/bpi/psnid/v6/5797
  2. Kinvig H, Rajoli RKR, Pertinez H, Vora LK, Volpe-Zanutto F, Donnelly RF, Rannard S, Flexner C, Siccardi M, Owen A. Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans. Pharmaceutics 2023;15(12):2709. https://doi.org/10.3390/pharmaceutics15122709
  3. Sae-Heng T, Rajoli RKR, Siccardi M & Na-Bangchang K. Dose Optimization of the Quinine-phenobarbital Co-administration in Cerebral Malaria Patients: A Physiologically-based Pharmacokinetic Modelling Approach. Novel Aspects on Pharmaceutical Research, Vol. 5 2023; pp. 117-138. https://doi.org/10.9734/bpi/napr/v5/19726d
  4. Walker LE, FitzGerald R, Saunders G, Lyon R, Fisher M, Martin K, et al. An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. Clinical Pharmacology & Therapeutics 2022 Mar;111(3):585-94. https://doi.org/10.1002/cpt.2463
  5. Sacramento CQ, Fintelman-Rodrigues N, Dias SSG, Temerozo JR, Da Silva APD, da Silva CS, et al. Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. Viruses 2022 Feb 11;14(2). https://doi.org/10.3390/v14020374
  6. Sae-Heng T, Rajoli RKR, Siccardi M, Karbwang J, Na-Bangchang K. Physiologically based pharmacokinetic modelling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria. CPT: Pharmacometrics & Systems Pharmacology 2022 Jan;11(1):104-15. https://doi.org/10.1002/psp4.12737
  7. Pertinez H, Rajoli RKR, Khoo SH, Owen A. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. Journal of Antimicrobial Chemotherapy 2021 Jul 15;76(8):2121-8. https://doi.org/10.1093/jac/dkab135
  8. Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Da Silva APD, Dias S, da Silva CDS, et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. Journal of Antimicrobial Chemotherapy 2021 Jun 18;76(7):1874-85. https://doi.org/10.1093/jac/dkab072
  9. Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, et al. Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. British Journal of Clinical Pharmacology 2021 Apr;87(4):2078-88. https://doi.org/10.1111/bcp.14619
  10. Saeheng T, Na-Bangchang K, Siccardi M, Rajoli RKR, Karbwang J. Physiologically-Based Pharmacokinetic Modelling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir. Clinical Pharmacology & Therapeutics 2020 May;107(5):1209-20. https://doi.org/10.1002/cpt.1721
  11. Rajoli RKR, Demkovich ZR, Flexner C, Owen A, Siccardi M. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. Antimicrobial Agents and Chemotherapy 2020 Jul 22;64(8). https://doi.org/10.1128/AAC.00155-20
  12. Bunglawala F, Rajoli RKR, Mirochnick M, Owen A, Siccardi M. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. Journal of Antimicrobial Chemotherapy 2020 Mar 1;75(3):640-7. https://doi.org/10.1093/jac/dkz506
  13. Rajoli RKR, Flexner C, Chiong J, Owen A, Donnelly RF, Larraneta E, et al. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. European Journal of Pharmaceutics and Biopharmaceutics 2019 Nov;144:101-9. https://doi.org/10.1016/j.ejpb.2019.09.011
  14. Rajoli RKR, Curley P, Chiong J, Back D, Flexner C, Owen A, et al. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modelling. Journal of Infectious Diseases 2019 May 5;219(11):1735-42. https://doi.org/10.1093/infdis/jiy726
  15. Atoyebi SA, Rajoli RKR, Adejuyigbe E, Owen A, Bolaji O, Siccardi M, et al. Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. European Journal of Pharmaceutical Sciences 2019 Dec 1;140:105068. https://doi.org/10.1016/j.ejps.2019.105068
  16. Roberts O, Rajoli RKR, Back DJ, Owen A, Darin KM, Fletcher CV, et al. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy 2018 Apr 1;73(4):1004-12. https://doi.org/10.1093/jac/dkx515
  17. Rajoli RKR, Podany AT, Moss DM, Swindells S, Flexner C, Owen A, et al. Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. International Journal of Tuberculosis and Lung Disease 2018 Aug 1;22(8):937-44. https://doi.org/10.5588/ijtld.17.0515
  18. Rajoli RKR, Back DJ, Rannard S, Meyers CF, Flexner C, Owen A, et al. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. Clinical Pharmacokinetics 2018 Feb;57(2):255-66. https://doi.org/10.1007/s40262-017-0557-x
  19. Molto J, Rajoli R, Back D, Valle M, Miranda C, Owen A, et al. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. Journal of Antimicrobial Chemotherapy 2017 Mar 1;72(3):805-11. https://doi.org/10.1093/jac/dkw485
  20. Marzolini C, Rajoli R, Battegay M, Elzi L, Back D, Siccardi M. Physiologically Based Pharmacokinetic Modelling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Clinical Pharmacokinetics 2017 Apr;56(4):409-20. https://doi.org/10.1007/s40262-016-0447-7
  21. Curley P, Rajoli RK, Moss DM, Liptrott NJ, Letendre S, Owen A, et al. Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. Antimicrobial Agents and Chemotherapy 2017 Jan;61(1). https://doi.org/10.1128/AAC.01841-16
  22. Rajoli RK, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, et al. Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. Clinical Pharmacokinetics 2015 Jun;54(6):639-50. https://doi.org/10.1007/s40262-014-0227-1
< NCA
Team >